Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 4Phase 1/2 4Phase 3 3Phase EARLY_PHASE1 2

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Ovarian Neoplasms 28Small Cell Lung Carcinoma 24Fallopian Tube Neoplasms 12Uterine Cervical Neoplasms 8Carcinoma, Ovarian Epithelial 8Neuroblastoma 7Lung Neoplasms 6Sarcoma 3Neoplasms 3Retinoblastoma 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Ganglioneuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Localized Extraskeletal Ewing Sarcoma 1Leukemia 1Eye Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Topotecan × Clear all
NCT07365241 2026-01-26

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Not yet recruiting
531 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Xian-Janssen Pharmaceutical Ltd.

Phase 3 Terminated
32 enrolled 13 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡